Please Wait
Applying Filters...
Xls
2D Structure
Also known as: Propyleneimine, Propylenimine, Aziridine, 2-methyl-, 75-55-8, Methylaziridine, 1,2-propylenimine
Molecular Formula
C3H7N
Molecular Weight
57.09  g/mol
InChI Key
OZDGMOYKSFPLSE-UHFFFAOYSA-N
FDA UNII
ULC972Q7TZ

Propylenimine is a synthetic, flammable, volatile, colorless oily liquid that is soluble in water, ethanol and most organic solvents. Propylenimine is used in the United States exclusively as an intermediate, and its derivatives are used in the paper, textile, rubber and pharmaceutical industries. Due to its volatility, potential exposure could occur during production, packaging, or use of substances made with this liquid. The primary routes of potential human exposure to propylenimine are inhalation, ingestion and dermal contact. It is reasonably anticipated to be a human carcinogen. (NCI05)
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-methylaziridine
2.1.2 InChI
InChI=1S/C3H7N/c1-3-2-4-3/h3-4H,2H2,1H3
2.1.3 InChI Key
OZDGMOYKSFPLSE-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1CN1
2.2 Other Identifiers
2.2.1 UNII
ULC972Q7TZ
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Propylene Imine

2. Propyleneimine

2.3.2 Depositor-Supplied Synonyms

1. Propyleneimine

2. Propylenimine

3. Aziridine, 2-methyl-

4. 75-55-8

5. Methylaziridine

6. 1,2-propylenimine

7. 2-methylethylenimine

8. Methylethylenimine

9. 1,2-propyleneimine

10. 2-methylazacyclopropane

11. 2-methyl Aziridine

12. Rcra Waste Number P067

13. Nsc 20655

14. Propyleneimine, Inhibited

15. Ulc972q7tz

16. Chebi:82340

17. Propylene Imine

18. 2-methylaziridine (propylenimine)

19. Nsc-20655

20. Propilenimina

21. Propilenimina [spanish]

22. S-2-methylaziridine

23. Ccris 539

24. Hsdb 739

25. Dl-2-methylaziridine

26. Einecs 200-878-7

27. Un1921

28. Rcra Waste No. P067

29. Unii-ulc972q7tz

30. Brn 0102386

31. Ai3-50325

32. Dsstox_cid_4286

33. Ec 200-878-7

34. Wln: T3mtj B1

35. Dsstox_rid_77355

36. Dsstox_gsid_24286

37. Propyleneimine [hsdb]

38. 5-20-01-00150 (beilstein Handbook Reference)

39. Un 1921 (salt/mix)

40. Chembl3183775

41. Dtxsid8024286

42. Ozdgmoyksfplse-uhfffaoysa-

43. 2-methylaziridine [iarc]

44. 2-?methylaziridine (propylenimine)

45. Nsc20655

46. Tox21_202944

47. Stl168051

48. 2-methylaziridine, (+/-)-

49. Akos005366679

50. Cas-75-55-8

51. Ncgc00260490-01

52. 2-methylaziridine, Technical Grade, 90%

53. Db-016804

54. Ft-0649217

55. C19257

56. Q7250470

57. Propyleneimine, Inhibited [un1921] [flammable Liquid]

2.4 Create Date
2005-03-26
3 Chemical and Physical Properties
Molecular Weight 57.09 g/mol
Molecular Formula C3H7N
XLogP30
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count1
Rotatable Bond Count0
Exact Mass57.057849228 g/mol
Monoisotopic Mass57.057849228 g/mol
Topological Polar Surface Area21.9 Ų
Heavy Atom Count4
Formal Charge0
Complexity26.5
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 Mechanism of Action

The application of (1)H nuclear magnetic resonance (NMR) spectroscopy to the study of the biochemical effects of six nephrotoxic compounds, including mercury-chloride (HgCl2), was investigated in the male Fischer-344-rat. The rats were treated with nephrotoxic doses of sodium-chromate, cisplatin, hexachlorobutadiene, HgCl2, propylene-imine, and bromoethanamine. 1H-NMR spectroscopy and conventional biochemical methods were used to provide biochemical fingerprints of urine collected up to 48 hours after dosing. Severe glycosuria and transient enzymuria were produced by hexachlorobutadiene and HgCl2. Aminoaciduria, glycosuria, and lactic aciduria were noted after exposure to all proximal tubular toxins with the exception of cisplatin. Papillary insult resulted in early elevations in urinary trimethylamine-N-oxide and dimethylamine, together with later elevations in urinary acetate, succinate, and N,N-dimethylglycine /after propylene-imine/.

Gartland KP et al; Mol Pharmcol 35 (2): 242-250 (1989)